Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Free Report) Director Alessandra Cesano sold 62,150 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $9.12, for a total transaction of $566,808.00. Following the transaction, the director owned 56,700 shares in the company, valued at $517,104. The trade was a 52.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Puma Biotechnology Trading Up 1.5%
Shares of PBYI traded up $0.14 during mid-day trading on Wednesday, reaching $9.39. The company’s stock had a trading volume of 188,827 shares, compared to its average volume of 288,825. The stock has a market cap of $484.71 million, a PE ratio of 18.06 and a beta of 1.24. Puma Biotechnology, Inc. has a 52 week low of $4.30 and a 52 week high of $9.73. The company’s fifty day moving average price is $8.71 and its two-hundred day moving average price is $7.65.
Puma Biotechnology (NASDAQ:PBYI – Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.04 by $0.15. The company had revenue of $56.50 million for the quarter, compared to analyst estimates of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 20.76%. Research analysts anticipate that Puma Biotechnology, Inc. will post 0.37 EPS for the current year.
Institutional Investors Weigh In On Puma Biotechnology
Analysts Set New Price Targets
Several brokerages have weighed in on PBYI. Weiss Ratings raised shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Wall Street Zen raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. Finally, TD Cowen increased their price objective on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a report on Friday, August 7th. Two analysts have rated the stock with a Hold rating, According to MarketBeat.com, Puma Biotechnology currently has a consensus rating of “Hold” and a consensus price target of $6.00.
Get Our Latest Stock Report on Puma Biotechnology
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company focused on developing and commercializing medicines for the treatment of cancer. The company’s primary product is NERLYNX (neratinib), an oral tyrosine kinase inhibitor designed to target HER2 and other members of the human epidermal growth factor receptor family.
In the United States, NERLYNX is approved for the extended adjuvant treatment of adults with early-stage HER2-positive breast cancer following postoperative trastuzumab-based therapy.
Recommended Stories
- Five stocks we like better than Puma Biotechnology
- 3 Luxury Consumer Brands to Watch in a Beaten-Down Sector
- Jackson’s Record Quarter Powers the Bull Case
- Holiday Shopping Is Almost Here—And Target May Be Ready to Win Big
- AI Panic Hit Tech Stocks—But NVIDIA’s Growth Engine Is Intact
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
